CovidChloroV1, Main, Curation, bibRecord, 001440

Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype?

Identifieur interne : 001440 ( Main/Curation ); précédent : 001439; suivant : 001441

Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype?

Auteurs : Patrick Brest [France] ; Jonathan Benzaquen [France] ; Daniel J. Klionsky [États-Unis] ; Paul Hofman [France] ; Baharia Mograbi [France]

Source :

Autophagy [ 1554-8635 ] ; 2020.

RBID : pubmed:32521191

Descripteurs français

KwdFr :
- Anti-inflammatoires (pharmacologie), Anti-inflammatoires (usage thérapeutique), Antiviraux (pharmacologie), Antiviraux (usage thérapeutique), Autophagie (effets des médicaments et des substances chimiques), Autophagie (physiologie), Chloroquine (analogues et dérivés), Chloroquine (pharmacologie), Chloroquine (usage thérapeutique), Ebolavirus (effets des médicaments et des substances chimiques), Effets secondaires indésirables des médicaments (épidémiologie), Histoire du 21ème siècle (MeSH), Humains (MeSH), Hydroxychloroquine (pharmacologie), Hydroxychloroquine (usage thérapeutique), Paludisme (traitement médicamenteux), Pandémies (MeSH), Plasmodium malariae (effets des médicaments et des substances chimiques), Repositionnement des médicaments (méthodes), Repositionnement des médicaments (tendances), Transduction du signal (effets des médicaments et des substances chimiques), Transduction du signal (immunologie), VIH (Virus de l'Immunodéficience Humaine) (effets des médicaments et des substances chimiques), Éradication de maladie (méthodes).
MESH :
- analogues et dérivés : Chloroquine.
- effets des médicaments et des substances chimiques : Autophagie, Ebolavirus, Plasmodium malariae, Transduction du signal, VIH (Virus de l'Immunodéficience Humaine).
- immunologie : Transduction du signal.
- méthodes : Repositionnement des médicaments, Éradication de maladie.
- pharmacologie : Anti-inflammatoires, Antiviraux, Chloroquine, Hydroxychloroquine.
- physiologie : Autophagie.
- tendances : Repositionnement des médicaments.
- traitement médicamenteux : Paludisme.
- usage thérapeutique : Anti-inflammatoires, Antiviraux, Chloroquine, Hydroxychloroquine.
- épidémiologie : Effets secondaires indésirables des médicaments.
- Histoire du 21ème siècle, Humains, Pandémies.

English descriptors

KwdEn :
- Anti-Inflammatory Agents (pharmacology), Anti-Inflammatory Agents (therapeutic use), Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), Autophagy (drug effects), Autophagy (physiology), COVID-19 (drug therapy), COVID-19 (epidemiology), COVID-19 (immunology), COVID-19 (pathology), Chloroquine (analogs & derivatives), Chloroquine (pharmacology), Chloroquine (therapeutic use), Disease Eradication (methods), Drug Repositioning (methods), Drug Repositioning (trends), Drug-Related Side Effects and Adverse Reactions (epidemiology), Ebolavirus (drug effects), HIV (drug effects), History, 21st Century (MeSH), Humans (MeSH), Hydroxychloroquine (pharmacology), Hydroxychloroquine (therapeutic use), Malaria (drug therapy), Pandemics (MeSH), Plasmodium malariae (drug effects), SARS-CoV-2 (drug effects), SARS-CoV-2 (immunology), SARS-CoV-2 (pathogenicity), Signal Transduction (drug effects), Signal Transduction (immunology).
MESH :
- chemical , analogs & derivatives : Chloroquine.
- chemical , pharmacology : Anti-Inflammatory Agents, Antiviral Agents, Chloroquine, Hydroxychloroquine.
- chemical , therapeutic use : Anti-Inflammatory Agents, Antiviral Agents, Chloroquine, Hydroxychloroquine.
- drug effects : Autophagy, Ebolavirus, HIV, Plasmodium malariae, SARS-CoV-2, Signal Transduction.
- drug therapy : COVID-19, Malaria.
- epidemiology : COVID-19, Drug-Related Side Effects and Adverse Reactions.
- immunology : COVID-19, SARS-CoV-2, Signal Transduction.
- methods : Disease Eradication, Drug Repositioning.
- pathogenicity : SARS-CoV-2.
- pathology : COVID-19.
- physiology : Autophagy.
- trends : Drug Repositioning.
- History, 21st Century, Humans, Pandemics.

Abstract

At a time when the world faces an emotional breakdown, crushing our dreams, if not, taking our lives, we realize that together we must fight the war against the COVID-19 outbreak even if almost the majority of the scientific community finds itself confined at home. Every day, we, scientists, listen to the latest news with its promises and announcements. Across the world, a surge of clinical trials trying to cure or slow down the coronavirus pandemic has been launched to bring hope instead of fear and despair. One first proposed clinical trial has drawn worldwide hype to the benefit of chloroquine (CQ), in the treatment of patients infected by the recently emerged deadly coronavirus (SARS-CoV-2). We should consider this information in light of the long-standing anti-inflammatory and anti-viral properties of CQ-related drugs. Yet, none of the articles promoting the use of CQ in the current pandemic evoked a possible molecular or cellular mechanism of action that could account for any efficacy. Here, given the interaction of viruses with macroautophagy (hereafter referred to as autophagy), a CQ-sensitive anti-viral safeguard pathway, we would like to discuss the pros, but also the cons concerning the current therapeutic options targeting this process.

DOI: 10.1080/15548627.2020.1779531
PubMed: 32521191
PubMed Central: PMC7751564

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001440

Links to Exploration step

pubmed:32521191

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype?</title>
<author><name sortKey="Brest, Patrick" sort="Brest, Patrick" uniqKey="Brest P" first="Patrick" last="Brest">Patrick Brest</name>
<affiliation wicri:level="1"><nlm:affiliation>Universitty Côte d'Azur, IRCAN, CNRS , INSERM, Centre Antoine Lacassagne, FHU-OncoAge , Nice, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Universitty Côte d'Azur, IRCAN, CNRS , INSERM, Centre Antoine Lacassagne, FHU-OncoAge , Nice</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Benzaquen, Jonathan" sort="Benzaquen, Jonathan" uniqKey="Benzaquen J" first="Jonathan" last="Benzaquen">Jonathan Benzaquen</name>
<affiliation wicri:level="1"><nlm:affiliation>Universitty Côte d'Azur, IRCAN, CNRS , INSERM, Centre Antoine Lacassagne, FHU-OncoAge , Nice, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Universitty Côte d'Azur, IRCAN, CNRS , INSERM, Centre Antoine Lacassagne, FHU-OncoAge , Nice</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Université Côte d'Azur, CHU De Nice, Department of Pulmonary Medicine and Oncology , Nice, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Université Côte d'Azur, CHU De Nice, Department of Pulmonary Medicine and Oncology , Nice</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Klionsky, Daniel J" sort="Klionsky, Daniel J" uniqKey="Klionsky D" first="Daniel J" last="Klionsky">Daniel J. Klionsky</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular, Cellular, and Developmental Biology, Life Sciences Institute, University of Michigan , Ann Arbor, MI, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Molecular, Cellular, and Developmental Biology, Life Sciences Institute, University of Michigan , Ann Arbor, MI</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hofman, Paul" sort="Hofman, Paul" uniqKey="Hofman P" first="Paul" last="Hofman">Paul Hofman</name>
<affiliation wicri:level="1"><nlm:affiliation>Université Côte d'Azur, CHU De Nice, Laboratory of Clinical and Experimental Pathology (LPCE) , Nice, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Université Côte d'Azur, CHU De Nice, Laboratory of Clinical and Experimental Pathology (LPCE) , Nice</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mograbi, Baharia" sort="Mograbi, Baharia" uniqKey="Mograbi B" first="Baharia" last="Mograbi">Baharia Mograbi</name>
<affiliation wicri:level="1"><nlm:affiliation>Universitty Côte d'Azur, IRCAN, CNRS , INSERM, Centre Antoine Lacassagne, FHU-OncoAge , Nice, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Universitty Côte d'Azur, IRCAN, CNRS , INSERM, Centre Antoine Lacassagne, FHU-OncoAge , Nice</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Université Côte d'Azur, CHU De Nice, Laboratory of Clinical and Experimental Pathology (LPCE) , Nice, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Université Côte d'Azur, CHU De Nice, Laboratory of Clinical and Experimental Pathology (LPCE) , Nice</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32521191</idno>
<idno type="pmid">32521191</idno>
<idno type="doi">10.1080/15548627.2020.1779531</idno>
<idno type="pmc">PMC7751564</idno>
<idno type="wicri:Area/Main/Corpus">001440</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001440</idno>
<idno type="wicri:Area/Main/Curation">001440</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001440</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype?</title>
<author><name sortKey="Brest, Patrick" sort="Brest, Patrick" uniqKey="Brest P" first="Patrick" last="Brest">Patrick Brest</name>
<affiliation wicri:level="1"><nlm:affiliation>Universitty Côte d'Azur, IRCAN, CNRS , INSERM, Centre Antoine Lacassagne, FHU-OncoAge , Nice, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Universitty Côte d'Azur, IRCAN, CNRS , INSERM, Centre Antoine Lacassagne, FHU-OncoAge , Nice</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Benzaquen, Jonathan" sort="Benzaquen, Jonathan" uniqKey="Benzaquen J" first="Jonathan" last="Benzaquen">Jonathan Benzaquen</name>
<affiliation wicri:level="1"><nlm:affiliation>Universitty Côte d'Azur, IRCAN, CNRS , INSERM, Centre Antoine Lacassagne, FHU-OncoAge , Nice, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Universitty Côte d'Azur, IRCAN, CNRS , INSERM, Centre Antoine Lacassagne, FHU-OncoAge , Nice</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Université Côte d'Azur, CHU De Nice, Department of Pulmonary Medicine and Oncology , Nice, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Université Côte d'Azur, CHU De Nice, Department of Pulmonary Medicine and Oncology , Nice</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Klionsky, Daniel J" sort="Klionsky, Daniel J" uniqKey="Klionsky D" first="Daniel J" last="Klionsky">Daniel J. Klionsky</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular, Cellular, and Developmental Biology, Life Sciences Institute, University of Michigan , Ann Arbor, MI, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Molecular, Cellular, and Developmental Biology, Life Sciences Institute, University of Michigan , Ann Arbor, MI</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hofman, Paul" sort="Hofman, Paul" uniqKey="Hofman P" first="Paul" last="Hofman">Paul Hofman</name>
<affiliation wicri:level="1"><nlm:affiliation>Université Côte d'Azur, CHU De Nice, Laboratory of Clinical and Experimental Pathology (LPCE) , Nice, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Université Côte d'Azur, CHU De Nice, Laboratory of Clinical and Experimental Pathology (LPCE) , Nice</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mograbi, Baharia" sort="Mograbi, Baharia" uniqKey="Mograbi B" first="Baharia" last="Mograbi">Baharia Mograbi</name>
<affiliation wicri:level="1"><nlm:affiliation>Universitty Côte d'Azur, IRCAN, CNRS , INSERM, Centre Antoine Lacassagne, FHU-OncoAge , Nice, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Universitty Côte d'Azur, IRCAN, CNRS , INSERM, Centre Antoine Lacassagne, FHU-OncoAge , Nice</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Université Côte d'Azur, CHU De Nice, Laboratory of Clinical and Experimental Pathology (LPCE) , Nice, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Université Côte d'Azur, CHU De Nice, Laboratory of Clinical and Experimental Pathology (LPCE) , Nice</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Autophagy</title>
<idno type="eISSN">1554-8635</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Inflammatory Agents (pharmacology)</term>
<term>Anti-Inflammatory Agents (therapeutic use)</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Autophagy (drug effects)</term>
<term>Autophagy (physiology)</term>
<term>COVID-19 (drug therapy)</term>
<term>COVID-19 (epidemiology)</term>
<term>COVID-19 (immunology)</term>
<term>COVID-19 (pathology)</term>
<term>Chloroquine (analogs & derivatives)</term>
<term>Chloroquine (pharmacology)</term>
<term>Chloroquine (therapeutic use)</term>
<term>Disease Eradication (methods)</term>
<term>Drug Repositioning (methods)</term>
<term>Drug Repositioning (trends)</term>
<term>Drug-Related Side Effects and Adverse Reactions (epidemiology)</term>
<term>Ebolavirus (drug effects)</term>
<term>HIV (drug effects)</term>
<term>History, 21st Century (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (pharmacology)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Malaria (drug therapy)</term>
<term>Pandemics (MeSH)</term>
<term>Plasmodium malariae (drug effects)</term>
<term>SARS-CoV-2 (drug effects)</term>
<term>SARS-CoV-2 (immunology)</term>
<term>SARS-CoV-2 (pathogenicity)</term>
<term>Signal Transduction (drug effects)</term>
<term>Signal Transduction (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Anti-inflammatoires (pharmacologie)</term>
<term>Anti-inflammatoires (usage thérapeutique)</term>
<term>Antiviraux (pharmacologie)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Autophagie (effets des médicaments et des substances chimiques)</term>
<term>Autophagie (physiologie)</term>
<term>Chloroquine (analogues et dérivés)</term>
<term>Chloroquine (pharmacologie)</term>
<term>Chloroquine (usage thérapeutique)</term>
<term>Ebolavirus (effets des médicaments et des substances chimiques)</term>
<term>Effets secondaires indésirables des médicaments (épidémiologie)</term>
<term>Histoire du 21ème siècle (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Hydroxychloroquine (pharmacologie)</term>
<term>Hydroxychloroquine (usage thérapeutique)</term>
<term>Paludisme (traitement médicamenteux)</term>
<term>Pandémies (MeSH)</term>
<term>Plasmodium malariae (effets des médicaments et des substances chimiques)</term>
<term>Repositionnement des médicaments (méthodes)</term>
<term>Repositionnement des médicaments (tendances)</term>
<term>Transduction du signal (effets des médicaments et des substances chimiques)</term>
<term>Transduction du signal (immunologie)</term>
<term>VIH (Virus de l'Immunodéficience Humaine) (effets des médicaments et des substances chimiques)</term>
<term>Éradication de maladie (méthodes)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Chloroquine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-Inflammatory Agents</term>
<term>Antiviral Agents</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Inflammatory Agents</term>
<term>Antiviral Agents</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Chloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Autophagy</term>
<term>Ebolavirus</term>
<term>HIV</term>
<term>Plasmodium malariae</term>
<term>SARS-CoV-2</term>
<term>Signal Transduction</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term>
<term>Malaria</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Autophagie</term>
<term>Ebolavirus</term>
<term>Plasmodium malariae</term>
<term>Transduction du signal</term>
<term>VIH (Virus de l'Immunodéficience Humaine)</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>COVID-19</term>
<term>Drug-Related Side Effects and Adverse Reactions</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Transduction du signal</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>COVID-19</term>
<term>SARS-CoV-2</term>
<term>Signal Transduction</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Disease Eradication</term>
<term>Drug Repositioning</term>
</keywords>
<keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Repositionnement des médicaments</term>
<term>Éradication de maladie</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Anti-inflammatoires</term>
<term>Antiviraux</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Autophagie</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Autophagy</term>
</keywords>
<keywords scheme="MESH" qualifier="tendances" xml:lang="fr"><term>Repositionnement des médicaments</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Paludisme</term>
</keywords>
<keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Drug Repositioning</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anti-inflammatoires</term>
<term>Antiviraux</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Effets secondaires indésirables des médicaments</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>History, 21st Century</term>
<term>Humans</term>
<term>Pandemics</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Histoire du 21ème siècle</term>
<term>Humains</term>
<term>Pandémies</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">At a time when the world faces an emotional breakdown, crushing our dreams, if not, taking our lives, we realize that together we must fight the war against the COVID-19 outbreak even if almost the majority of the scientific community finds itself confined at home. Every day, we, scientists, listen to the latest news with its promises and announcements. Across the world, a surge of clinical trials trying to cure or slow down the coronavirus pandemic has been launched to bring hope instead of fear and despair. One first proposed clinical trial has drawn worldwide hype to the benefit of chloroquine (CQ), in the treatment of patients infected by the recently emerged deadly coronavirus (SARS-CoV-2). We should consider this information in light of the long-standing anti-inflammatory and anti-viral properties of CQ-related drugs. Yet, none of the articles promoting the use of CQ in the current pandemic evoked a possible molecular or cellular mechanism of action that could account for any efficacy. Here, given the interaction of viruses with macroautophagy (hereafter referred to as autophagy), a CQ-sensitive anti-viral safeguard pathway, we would like to discuss the pros, but also the cons concerning the current therapeutic options targeting this process.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32521191</PMID>
<DateCompleted><Year>2020</Year>
<Month>12</Month>
<Day>30</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>04</Month>
<Day>22</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1554-8635</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>16</Volume>
<Issue>12</Issue>
<PubDate><Year>2020</Year>
<Month>12</Month>
</PubDate>
</JournalIssue>
<Title>Autophagy</Title>
<ISOAbbreviation>Autophagy</ISOAbbreviation>
</Journal>
<ArticleTitle>Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype?</ArticleTitle>
<Pagination><MedlinePgn>2267-2270</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1080/15548627.2020.1779531</ELocationID>
<Abstract><AbstractText>At a time when the world faces an emotional breakdown, crushing our dreams, if not, taking our lives, we realize that together we must fight the war against the COVID-19 outbreak even if almost the majority of the scientific community finds itself confined at home. Every day, we, scientists, listen to the latest news with its promises and announcements. Across the world, a surge of clinical trials trying to cure or slow down the coronavirus pandemic has been launched to bring hope instead of fear and despair. One first proposed clinical trial has drawn worldwide hype to the benefit of chloroquine (CQ), in the treatment of patients infected by the recently emerged deadly coronavirus (SARS-CoV-2). We should consider this information in light of the long-standing anti-inflammatory and anti-viral properties of CQ-related drugs. Yet, none of the articles promoting the use of CQ in the current pandemic evoked a possible molecular or cellular mechanism of action that could account for any efficacy. Here, given the interaction of viruses with macroautophagy (hereafter referred to as autophagy), a CQ-sensitive anti-viral safeguard pathway, we would like to discuss the pros, but also the cons concerning the current therapeutic options targeting this process.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brest</LastName>
<ForeName>Patrick</ForeName>
<Initials>P</Initials>
<Identifier Source="ORCID">0000-0002-1252-4747</Identifier>
<AffiliationInfo><Affiliation>Universitty Côte d'Azur, IRCAN, CNRS , INSERM, Centre Antoine Lacassagne, FHU-OncoAge , Nice, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Benzaquen</LastName>
<ForeName>Jonathan</ForeName>
<Initials>J</Initials>
<Identifier Source="ORCID">0000-0002-1899-9612</Identifier>
<AffiliationInfo><Affiliation>Universitty Côte d'Azur, IRCAN, CNRS , INSERM, Centre Antoine Lacassagne, FHU-OncoAge , Nice, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Université Côte d'Azur, CHU De Nice, Department of Pulmonary Medicine and Oncology , Nice, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Klionsky</LastName>
<ForeName>Daniel J</ForeName>
<Initials>DJ</Initials>
<Identifier Source="ORCID">0000-0002-7828-8118</Identifier>
<AffiliationInfo><Affiliation>Department of Molecular, Cellular, and Developmental Biology, Life Sciences Institute, University of Michigan , Ann Arbor, MI, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hofman</LastName>
<ForeName>Paul</ForeName>
<Initials>P</Initials>
<Identifier Source="ORCID">0000-0003-0431-9353</Identifier>
<AffiliationInfo><Affiliation>Université Côte d'Azur, CHU De Nice, Laboratory of Clinical and Experimental Pathology (LPCE) , Nice, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mograbi</LastName>
<ForeName>Baharia</ForeName>
<Initials>B</Initials>
<Identifier Source="ORCID">0000-0002-1025-3429</Identifier>
<AffiliationInfo><Affiliation>Universitty Côte d'Azur, IRCAN, CNRS , INSERM, Centre Antoine Lacassagne, FHU-OncoAge , Nice, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Université Côte d'Azur, CHU De Nice, Laboratory of Clinical and Experimental Pathology (LPCE) , Nice, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>R35 GM131919</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016456">Historical Article</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>06</Month>
<Day>19</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Autophagy</MedlineTA>
<NlmUniqueID>101265188</NlmUniqueID>
<ISSNLinking>1554-8627</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>886U3H6UFF</RegistryNumber>
<NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D060740" MajorTopicYN="N">Disease Eradication</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
<QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D029043" MajorTopicYN="N">Ebolavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006678" MajorTopicYN="N">HIV</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D049674" MajorTopicYN="N">History, 21st Century</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008288" MajorTopicYN="N">Malaria</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010965" MajorTopicYN="N">Plasmodium malariae</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Anti-viral</Keyword>
<Keyword MajorTopicYN="Y">COVID-19</Keyword>
<Keyword MajorTopicYN="Y">hydroxychloroquine</Keyword>
<Keyword MajorTopicYN="Y">immunology</Keyword>
<Keyword MajorTopicYN="Y">infection</Keyword>
<Keyword MajorTopicYN="Y">inflammation</Keyword>
<Keyword MajorTopicYN="Y">lysophagy</Keyword>
<Keyword MajorTopicYN="Y">microbiology</Keyword>
<Keyword MajorTopicYN="Y">plaquenil</Keyword>
<Keyword MajorTopicYN="Y">virophagy</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year>
<Month>06</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>6</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>12</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>6</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32521191</ArticleId>
<ArticleId IdType="doi">10.1080/15548627.2020.1779531</ArticleId>
<ArticleId IdType="pmc">PMC7751564</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Cell Discov. 2020 Mar 18;6(1):16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33731711</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2017 Jan 30;542(7639):25-27</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28150789</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):72-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32074550</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunity. 2013 Aug 22;39(2):211-27</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23973220</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5871-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19321428</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Netw Open. 2020 Apr 24;3(4):e208857</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32330277</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2013 Sep;87(18):9966-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23760248</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2020 May;20(5):533-534</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32087114</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Apr;55(4):105932</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32145363</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Methods. 2015 Mar;75:128-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25542097</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 22;395(10224):565-574</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32007145</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 1993 Jul 3;307(6895):49-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8343674</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Virol. 2001 Feb;20(3):137-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11166662</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Genet. 2011 Mar;43(3):242-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21278745</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>mBio. 2011 Aug 09;2(4):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21828219</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 May 19;323(19):1897-1898</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32208486</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2020 May 14;369:m1844</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32409486</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001440 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 001440 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:32521191
   |texte=   Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype?
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i   -Sk "pubmed:32521191" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype?

Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype?

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki